Differential Changes in Color and Motion-Onset Visual Evoked Potentials from Both Eyes in Early- and Late-Onset Strabismic Amblyopia

• Published in: Investigative ophthalmology & visual science 2008-10, Vol.49 (10), p.4418-4426
• Main Authors: Davis, Alison R, Sloper, John J, Neveu, Magella M, Hogg, Chris R, Morgan, Michael J, Holder, Graham E
• Format: Article
• Language: English
• Subjects: Adolescent; Adult; Amblyopia - physiopathology; Biological and medical sciences; Color Vision Defects - physiopathology; Contrast Sensitivity - physiology; Evoked Potentials, Visual - physiology; Eye and associated structures. Visual pathways and centers. Vision; Female; Fundamental and applied biological sciences. Psychology; Humans; Male; Medical sciences; Middle Aged; Motion Perception - physiology; Ophthalmology; Strabismus - physiopathology; Vertebrates: nervous system and sense organs; Vision disorders
• ISSN: 0146-0404; 1552-5783; 1552-5783
• DOI: 10.1167/iovs.07-1437

To examine changes in color- and motion-related visual function in patients with strabismic amblyopia. Motion-onset and color visual-evoked potentials (VEPs) were recorded in 16 adult patients with strabismic amblyopia which had an early onset, before 18 months of age, and 14 patients with amblyopia of later onset. The results are compared with those from 21 normal adults. The peak times of motion-onset VEPs in the amblyopic eye were longer those than in the fellow eye in patients with both early- and late-onset strabismic amblyopia, but peak times in both amblyopic and fellow eyes were shorter than those in normal eyes. In patients with late- but not early-onset amblyopia, the peak times for color VEPs were significantly longer in amblyopic than in fellow and normal eyes. The patterns of abnormality for motion-onset and color VEPs in patients with strabismic amblyopia are different, probably indicating differential changes in function in magno- and parvocellular pathways. These abnormalities affect both the amblyopic and fellow eyes and are different in patients with an onset of amblyopia before or after 18 months of age.